The U.S. Army has awarded Saab an Indefinite Delivery, Indefinite Quantity (IDIQ) contract, which allows the U.S. Army to place orders for up to $494 million over five years for the XM919 Individual Assault Munition (IAM) programme. Saab’s solution is the AT4CS TW (Confined Space Tandem Warhead).
Order values will be established individually when an order is placed under the IDIQ contract.
Saab’s new addition to the battle-tested AT4 family combines the capability of multiple existing shoulder-launched munitions while reducing soldier load, training complexity and logistics burden.
“At Saab, we continually adapt and improve our products to meet customer needs and protect the warfighter. Our new IAM solution enhances capabilities, removes combat burdens and is uniquely created to meet the U.S. customer’s needs,” said Erik Smith, president and CEO of Saab in the U.S.
“Saab has leveraged a successful, combat-proven system to make it even more effective, ultimately ensuring our solution is the best fit for the end-user.”
The AT4 is a battle-tested, successful anti-armor weapon with more than one million systems produced for 15 countries around the world. Lightweight, man-portable, and fully disposable, the AT4 has been the U.S. Army’s squad weapon since 1985. Saab has delivered more than 700,000 AT4 systems to the United States.
